HUS

New gene defect discovery helps to unlock the mystery of severe infectious mononucleosis

28.3.2024 09:35:39 EET | HUS | Press release

Share

A new hereditary disease was found in Finns, which manifests as severe infectious mononucleosis. The genetic defect can lead to the treatment of many different diseases.

Mikko Seppänen
A new gene defect was discovered in the Finnish population, which, if inherited from both parents, may cause severe infectious mononucleosis but also help you cope with it. Chief Physician Mikko Seppänen from HUS Children and Adolescents and the University of Helsinki took part in the international study published in the prestigious science journal Nature. Photo: Hanna Raijas-Turva / HUS

Almost all Finns suffer from symptomatic or asymptomatic “kissing disease”, or infectious mononucleosis (IM), at a young age, which is an infection caused by the Epstein-Barr virus (EBV). A small part of the patients requires hospital care.

About 95 per cent of Finns are infected with the Epstein-Barr virus, which spreads through saliva. Most are exposed to the virus as a child, either without symptoms or with infectious mononucleosis as the only symptom. The symptoms of severe infectious mononucleosis are usually fever and severely swollen lymph nodes and spleen. Symptoms requiring hospital care include severe inflammatory symptoms, severe lymphatic tissue hyperplasia (overgrowth), decline in general condition and rupture of the spleen.

New Finnish gene defect discovered

A new gene defect was discovered in the Finnish population, which, if inherited from both parents, may cause severe infectious mononucleosis but also help you cope with it. 

"This is a new hereditary disease in Finland, and around 300 Finns have it. One of its manifestations is severe infectious mononucleosis, which eventually heals on its own", says Chief Physician Mikko Seppänen from HUS Children and Adolescents and the University of Helsinki.

The study published in the prestigious science journal Nature was carried out in international cooperation, which also included one of the principal researchers of the FinnGen project, Mark Daly from the University of Helsinki.

Hope for new treatments for serious diseases

Some people with severe infectious mononucleosis are later diagnosed with other diseases associated with the Epstein-Barr virus, such as lymphatic tissue hyperplasia, which may lead to lymph node cancers or severe lymph node inflammation.

Everyone infected with the EBV carry the virus for the rest of their life. The study revealed that the gene defect prevented the gene from functioning, making it unable to communicate in its communication pathway. This led to a sudden inflammation with more symptoms than usual. At the same time, the gene defect surprisingly appeared to protect against uncontrolled general inflammation and life-threatening lymphatic tissue growth leading to tumor diseases. These can appear quickly in many hereditary immune deficiencies, or even decades later in drug-induced immune deficiencies. In other words, a functional gene was required for the uncontrolled overgrowth of lymphatic tissue.

"In the future, we are interested in whether the progression of lymphatic hyperplasia could be prevented by a treatment that silences the communication pathway found. If it works, we might be able to stop the progression of many of the most difficult blood cancers and lymph node tumors," Mikko Seppänen says.

The study monitored the patients for only a few years, so preparations for a new study have already begun. The aim is to find out whether Finnish biobanks and the children treated for infectious mononucleosis at the New Children's Hospital have this genetic defect.

"Biobank research can quickly determine whether these children should be prepared for the risk of an immune disease later in life. At the same time, we will find out the whole spectrum of the disease," says Seppänen.

Finnish biobanks and FinnGen project played a key role in the discovery

The study was launched at the Institute Imagine and Université Paris Cité, which specialize in genetic diseases in France, where three French children with severe infectious mononucleosis were examined for rare genetic defects. Severe mononucleosis infections are very rare in Central and Southern Europe.

Through HUS, the French contacted the FinnGen project, which covers the whole of Finland and contains genome and health register data for more than 540,000 Finns. An analysis carried out by FinnGen confirmed that the gene defect may cause severe infectious mononucleosis.

Kymenlaakso, Helsinki region and Savo have the highest number of carriers of the Finnish gene defect. The gene defect is approximately 50 times more common in Finns than in other populations.

Link to research article:
Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency

Contacts

Images

Mikko Seppänen
A new gene defect was discovered in the Finnish population, which, if inherited from both parents, may cause severe infectious mononucleosis but also help you cope with it. Chief Physician Mikko Seppänen from HUS Children and Adolescents and the University of Helsinki took part in the international study published in the prestigious science journal Nature.
Photo: Hanna Raijas-Turva / HUS
Download

About HUS

HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities. 

HUS treats almost 700,000 patients every year. Our nearly 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.

HUS – Leading healthcare 

Alternative languages

Subscribe to releases from HUS

Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from HUS

HUS delårsrapport för januari–september 202613.11.2026 15:45:22 EET | Pressmeddelande

Tredje kvartalet i korthet Antalet patienter som väntat länge på vård har minskat betydligt från årsskiftet. Under sommaren och början av hösten en ökning enligt den normala säsongsvariationen. Kundupplevelsen är på utmärkt nivå Personalsituationen på sammanslutningsnivå är god Det ekonomiska utfallet enligt plan Ekonomi Hållbar ekonomi är ett av HUS strategiska fokusområden. Räkenskapsperiodens resultat visade ett överskott på 68,2 miljoner euro och 81,5 miljoner över budgeten (budgeten -13,3 miljoner euro). Resultatet påverkades bland annat av en retroaktiv engångskorrigering av de fastighetsskatter som HUS betalt för åren 2015–2025, vilket förbättrar resultatet med cirka 22,7 miljoner euro. Den fjärde årsprognosen för 2026 utarbetades utgående från utfallet för januari–augusti. Enligt den beräknas resultatet för hela 2026 uppvisa ett överskott på 54,7 miljoner euro (budgeten för 2026 +/- 0 euro). Ekonomiska nyckeltal 1–9/2026: (1000 euro) Kumulativt utfall Förändring % (totalt/föreg

HUSin osavuosikatsaus tammi–syyskuu 202613.11.2026 15:45:22 EET | Tiedote

Kolmas neljännes lyhyesti Pitkään hoitoa odottaneiden määrä laskenut vuodenvaihteesta merkittävästi. Kesällä ja alkusyksystä normaalin kausivaihtelun mukaista nousua. Asiakaskokemus erinomaisella tasolla Henkilöstötilanne yhtymätasoisesti tarkastellen hyvä Talous toteutunut suunnitellusti Talous Kestävä talous on yksi HUSin strategisista painopisteistä. Tilikauden tulos on 68,2 miljoonaa euroa ylijäämäinen ja 81,5 miljoonaa euroa yli talousarvion (talousarvio -13,3 miljoonaa euroa). Tulokseen vaikutti muun muassa HUSin maksamien kiinteistöverojen takautuva kertaluonteinen oikaisu vuosilta 2015–2025, jonka tulosta parantava vaikutus on noin 22,7 miljoonaa euroa. Vuoden 2026 neljäs vuosiennuste laadittiin tammi–elokuun toteumatietojen pohjalta. Koko vuoden 2026 tilikauden tuloksen ennustetaan olevan 54,7 miljoonaa euroa ylijäämäinen (talousarvio 2026 +/- 0 euroa). Talouden tunnusluvut 1–9/2026: (1000 euroa) Toteuma kumulatiivinen Muutos % (tot/edv) Poikkeama % (tot/TA) Toimintatuotot 2 4

De nya lokalerna i Ohkola sjukhus stöder den rättspsykiatriska vården12.11.2026 08:30:00 EET | Pressmeddelande

HUS tar i bruk den nya sjukhusbyggnaden vid Ohkola sjukhus i Mäntsälä den 16 november 2026. Till nybyggnaden flyttar rättspsykiatriska avdelningar för stabiliserande vård och en del av de tjänster som stöder rehabiliteringen av patienter och sjukhusets verksamhet. Samtidigt fortsätter en del av verksamheten i den nuvarande sjukhusbyggnaden och därför är Ohkola sjukhus i fortsättningen en helhet som består av en gammal och en ny byggnadsdel.

Uudet tilat Ohkolan sairaalassa tukevat oikeuspsykiatrista hoitoa12.11.2026 08:30:00 EET | Tiedote

HUS ottaa käyttöön Mäntsälässä sijaitsevan Ohkolan sairaalan uuden sairaalarakennuksen 16. marraskuuta 2026. Uudisrakennukseen siirtyvät oikeuspsykiatrian vakauttavan hoidon osastot sekä osa potilaiden kuntoutusta ja sairaalan toimintaa tukevista palveluista. Samalla osa toiminnasta jatkuu nykyisessä sairaalarakennuksessa, joten Ohkolan sairaala muodostaa jatkossa yhden kokonaisuuden vanhasta ja uudesta rakennusosasta.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye